The radioisotopic measurement of gastric emptying offers information about an aspect of gastric motility. A procedure performed in our laboratory is presented. It is based on the ingestion of 500 ml saline including 1 mCi (3.7 MBq)113m In-DTPA or 99Tc-DTPA. The subject is placed in a half-supine position. Radioactive counts of the tracer are collected with a gammacamera and processed with a microcomputer, using a special program. This offers the histograms of the whole stomach and of the regions of interest (proximal and distal stomach), and also the half-time of these curves. Normal values range between 8-25 min for each curve half-time. The method has applications in physiology, pharmacology and clinical diagnosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Why are we still in need for novel anti-obesity medications?
Lancet Reg Health Eur
December 2024
Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany.
From the pioneering moment in 1987 when the insulinotropic effect of glucagon-like peptide 1 (GLP-1) was first demonstrated in humans, to today's pharmaceutical gold rush for GLP-1-based treatments of obesity, the journey of GLP-1 pharmacology has been nothing short of extraordinary. The sequential conceptual developments of long-acting GLP-1 receptor (GLP-1R) mono-agonists, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonists, and GLP-1R/GIPR/glucagon receptor (GcgR) triple agonists, have led to profound body weight-lowering capacities, with benefits that extend past obesity and towards obesity-associated diseases. The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain types of bariatric surgery.
View Article and Find Full Text PDFMassive gastrointestinal hemorrhage and iodine-125 seed migration due to hepatogastric fistula: a case report and literature review.
Transl Cancer Res
November 2024
Mini-invasive Intervention Center, The Third Affiliated Hospital of the Naval Medical University, Shanghai, China.
Background: Hepatogastric fistula (HGF) is an uncommon occurrence that can be associated with various medical conditions. The primary causes typically involve peptic ulcer disease, infections (such as pyogenic, amoebic or tuberculosis), or iatrogenic factors (like post transarterial chemoembolization or radiotherapy). Massive gastrointestinal hemorrhage following HGF is extremely rare, with iodine-125 (I) seed migration to the stomach through HGF not previously documented.
View Article and Find Full Text PDFEfficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents.
Endosc Int Open
December 2024
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, United States.
Endoscopic gastric remodeling (EGR) and anti-obesity medications (AOMs) are effective weight loss therapies. While the efficacy of EGR and AOMs has been established, the effect of combination therapy and its optimal approach remain unknown. This was a single-center retrospective review of prospectively collected data from patients who underwent EGR.
View Article and Find Full Text PDFMinimally Invasive Versus Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Trial Sequential Analysis of Randomized Trials.
Cancers (Basel)
December 2024
IRCCS Ospedale Galeazzi-Sant'Ambrogio, Division of General Surgery, Department of Biomedical Science for Health, University of Milan, Via C. Belgioioso, 173, 20157 Milan, Italy.
Background: Minimally invasive distal gastrectomy (MIDG) has been shown to be associated with improved short-term outcomes compared to open distal gastrectomy (ODG) in patients with locally advanced gastric cancer (LAGC). The impact of MIDG on long-term patient survival remains debated. Aim was to compare the MIDG vs.
View Article and Find Full Text PDFEvaluation of the safety, biodistribution, dosimetry of [F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial.
Eur J Nucl Med Mol Imaging
December 2024
Department of PET-CT, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Purpose: This first-in-human study aimed to evaluate the radiation dosimetry and whole-body biodistribution of [F]AlF-NYM005, a novel small-molecule carbonic anhydrase IX (CAIX) targeting agent, and to investigate its ability to detect CAIX-positive tumors using PET scans in a cohort of clear cell renal cell carcinoma (ccRCC) patients.
Methods: [F]AlF-NYM005 was synthesized using a fully automatic cassette module Mortenon M1 (Nuoyu, China). Thirty-five patients with a suspicious lesion considered primary renal malignancy or a history of ccRCC were prospectively recruited and studied.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!